欢迎来到天天文库
浏览记录
ID:53760598
大小:442.04 KB
页数:6页
时间:2020-04-24
《国内沙利度胺联合肝动脉化疗栓塞治疗原发性肝癌的Meta分析-论文.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、4年7月第8卷第l45.2014.、b1.8.No.14·循证医学·国内沙利度胺联合肝动脉化疗栓塞治疗原发性肝癌的Meta分析黄炽明符以恒杜嘉林刘全芳黄毅捷陈政波【摘要】目的评价沙利度胺联合肝动脉化疗栓塞治疗原发性肝癌的疗效。方法由两位独立研究员按相同检索策略通过计算机检索中国期刊全文数据库等资源中关于沙利度胺联合肝动脉化疗栓塞治疗原发性肝癌的文献资料,根据纳入及排除标准筛选出随机对照试验,按Cochrane系统评价方法评价文献质量后用RevMan5.2软件进行Meta分析。结果纳入16项研究,共1077例患者。Me
2、ta分析结果显示:沙利度胺联合肝动脉化疗栓塞术组与单纯肝动脉化疗栓塞术组比较,其有效率、疾病控制率及6个月、12个月、18个月、24个月、36个月的生存率均有所提高,差异均有统计学意义(OR效率=1.73,95%CI1-29~2.23,P=O.0002;ORB=2.08,95%C/1.48~2.93,P<0.0001:OR6十月=1.93,95%C/1.O7~3.49,P=0.03;OR12十月=1.91,95%C/1.42~2.57,P3、00O1;OR24Cn:2.03,95%C/1.42~2.90,P=0.0001:OR36个月=2.95,95%C/1.41~6.19,P=0.004)。结论沙利度胺联合肝动脉化疗栓塞术治疗与单独肝动脉化疗栓塞术治疗比较,能显著提高肝癌患者的治疗有效率、疾病控制率及6个月、l2个月、18个月、24个月、36个月的生存率。、【关键词】肝肿瘤;沙利度胺;肝动脉;化学栓塞,治疗性;Meta分析Thalidomidecombinedwiththanscatheterartierialchemoembolzationintre4、atmentofprimarylivercancerinChina:MetaanalysisHuangChiming,FuYiheng,DuJialinLiuQuanfang,HuangYijie,ChenZhengbo.DepartmentofGeneralSurgery,MedicalResearchCenter,GuangdongProvincialPeople'sHospital,GuangdongProvinceAcademyofMedicalSciences,Guangzhou510180,ChinaCo5、rrespondingauthor."HuangChiming,Email:hcm2353@sina.com[Abstract]ObjectiveToevaluatetheeffectivenessofthalidomidecombinedwiththanscatheterartierialchemoembolzation(TACE)inthetreatmentofprimarylivercancerLC).MethodsAccordingtotheCochranehandbookforsystematicrevie6、w,tworesearchersindependentlycollecteddatumaboutrandomizedcontrolledtrials(RCT)thatthecombinati0nofthalidomideandTACEfortreatmentofPLCfromdiferentdatabases(e.g.ChinaNationalKnowledgeInfrastructure,CNKI)accordingtoinclusionandexelusioncriteria.rnobtaineddatawere7、analyzedwithReviewManager5.2software.ResultsSixteenrandomizedcontrolledtrialswereincludedinthismeta—analysisandtotallyl077PLCpatientswereincluded.111eresultsofthemeta-analysisshowedthattheresponserate(IR),diseasecontrolrate(OCR)and6month,12month,18month,24month8、,36monthsurvivalrate,thecombinationofthalidomideandTACEweremuchbe~erthanthatofTACEalonefortreatmentofPLC.and恤erewerestatisticallysignificantdiference(ORm~-1.73,95%a1.29-2.23
3、00O1;OR24Cn:2.03,95%C/1.42~2.90,P=0.0001:OR36个月=2.95,95%C/1.41~6.19,P=0.004)。结论沙利度胺联合肝动脉化疗栓塞术治疗与单独肝动脉化疗栓塞术治疗比较,能显著提高肝癌患者的治疗有效率、疾病控制率及6个月、l2个月、18个月、24个月、36个月的生存率。、【关键词】肝肿瘤;沙利度胺;肝动脉;化学栓塞,治疗性;Meta分析Thalidomidecombinedwiththanscatheterartierialchemoembolzationintre
4、atmentofprimarylivercancerinChina:MetaanalysisHuangChiming,FuYiheng,DuJialinLiuQuanfang,HuangYijie,ChenZhengbo.DepartmentofGeneralSurgery,MedicalResearchCenter,GuangdongProvincialPeople'sHospital,GuangdongProvinceAcademyofMedicalSciences,Guangzhou510180,ChinaCo
5、rrespondingauthor."HuangChiming,Email:hcm2353@sina.com[Abstract]ObjectiveToevaluatetheeffectivenessofthalidomidecombinedwiththanscatheterartierialchemoembolzation(TACE)inthetreatmentofprimarylivercancerLC).MethodsAccordingtotheCochranehandbookforsystematicrevie
6、w,tworesearchersindependentlycollecteddatumaboutrandomizedcontrolledtrials(RCT)thatthecombinati0nofthalidomideandTACEfortreatmentofPLCfromdiferentdatabases(e.g.ChinaNationalKnowledgeInfrastructure,CNKI)accordingtoinclusionandexelusioncriteria.rnobtaineddatawere
7、analyzedwithReviewManager5.2software.ResultsSixteenrandomizedcontrolledtrialswereincludedinthismeta—analysisandtotallyl077PLCpatientswereincluded.111eresultsofthemeta-analysisshowedthattheresponserate(IR),diseasecontrolrate(OCR)and6month,12month,18month,24month
8、,36monthsurvivalrate,thecombinationofthalidomideandTACEweremuchbe~erthanthatofTACEalonefortreatmentofPLC.and恤erewerestatisticallysignificantdiference(ORm~-1.73,95%a1.29-2.23
此文档下载收益归作者所有